TY - JOUR AU - Rühle, Alexander AU - Todorovic, Jovan AU - Spohn, Simon S K AU - Gkika, Eleni AU - Becker, Christoph AU - Knopf, Andreas AU - Zamboglou, Constantinos AU - Sprave, Tanja AU - Werner, Martin AU - Grosu, Anca-Ligia AU - Kayser, Gian AU - Nicolay, Nils TI - Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy. JO - Radiation oncology VL - 17 IS - 1 SN - 1748-717X CY - London PB - BioMed Central M1 - DKFZ-2022-02787 SP - 181 PY - 2022 N1 - #EA:E055#LA:E055# AB - Tumor-infiltrating lymphocytes (TILs) are associated with locoregional control (LRC) in head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy. As immunosenescence results in reduced immune activity, the role of TILs in elderly HNSCC patients may differ compared to younger patients, providing a rationale to study the prognostic role of TILs and immune checkpoints (ICs) in this population.Sixty-three HNSCC patients aged ≥ 65 years undergoing definitive (chemo)radiotherapy between 2010 and 2019 with sufficient material from pre-treatment biopsies were included in the analysis. Immunohistochemical stainings of CD3, CD4, CD8, PD-L1, TIM3, LAG3, TIGIT and CD96, and of osteopontin as an immunosenescence-associated protein were performed. Overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method, and Fine-Gray's models were used for locoregional failure (LRF) analyses.While there was no correlation between patient age and IC expression, osteopontin levels correlated with increasing age (r = 0.322, p < 0.05). Two-year OS, PFS, and LRC were 44 KW - Elderly (Other) KW - Geriatric (Other) KW - Head-and-neck cancer (Other) KW - Immune checkpoint (Other) KW - Immunosenescence (Other) KW - Radiotherapy (Other) KW - Tumor-infiltrating lymphocytes (Other) LB - PUB:(DE-HGF)16 C6 - pmid:36376922 DO - DOI:10.1186/s13014-022-02153-9 UR - https://inrepo02.dkfz.de/record/182606 ER -